文章摘要
王广平,石晟怡,霍艳飞,江滨.所有制结构改革视角下的国有医药企业创新行为分析[J].中国药事,2018,32(2):172-179
所有制结构改革视角下的国有医药企业创新行为分析
On Innovative Behavior of State-owned Pharmaceutical Enterprises from the Perspective of Ownership Structure Reform
  修订日期:2017-07-17
DOI:10.16153/j.1002-7777.2018.02.003
中文关键词: 所有制结构  国有资本  医药企业  创新能力  绩效分析  结构调整
英文关键词: ownership structure  state-owned capital  pharmaceutical enterprise  innovation ability  performance analysis  structural adjustment
基金项目:国家社会科学基金资助项目我国药品监管模式优化研究(编号13BGL141)
作者单位
王广平 上海市食品药品安全研究中心, 上海 200233 
石晟怡 中国药科大学, 南京 210009 
霍艳飞 中国医药工业研究总院, 上海 200040 
江滨 北京大学药学院, 北京 100191 
摘要点击次数: 1232
全文下载次数: 719
中文摘要:
      目的:根据国有医药企业所具有的经济效益、社会责任和政治任务的特殊性,分析其在实施国家创新发展战略中的引领和示范作用,提出提升国有医药企业创新能力的路径。方法:基于医药所有制改革和创新政策的阐述,采用DEA(Data Envelopment Analysis,数据包络分析)的Malmquist(生产效率变化测算)指数,动态分析国有医药企业的创新绩效。采用Panel data(面板数据)模型对国有医药企业创新绩效进行实证分析。结果与结论:国有医药企业在生物产品制造业子领域取得了较好的创新绩效;国有企业是基于创新活动实现我国医药经济增长的主要力量,但还存在着研发资源过于集中和过剩现象。提升国有医药企业创新能力的路径,包括发挥其整合辐射作用、微观合作、组织结构调整和跨区域整合等。
英文摘要:
      Objective: To analyze the leading and exemplary role of the state-owned pharmaceutical enterprises in the implementation of national innovation and development strategies on the basis of their particularity in the economy, social responsibility and political task, and to put forward the methods of enhancing the innovative capacity of the state-owned pharmaceutical enterprises. Methods: Based on the analysis of medical ownership reform and innovation policy, the Malmquist index of Data Envelopment Analysis (DEA) was used to dynamically analyze the innovation performance of state-owned pharmaceutical enterprises. The panel data model was used to do the empirical analysis of the innovation performance of state-owned pharmaceutical enterprises. Results and Conclusion: The state-owned enterprises have fulflled good achievement in innovation in the subfeld of biological products manufacturing industry. The State-owned enterprises are the main force to achieve pharmaceutical economic growth of China, but the phenomenon of excessive concentration and surplus of research and development resources still exist. The way to enhance innovation ability of the state-owned pharmaceutical enterprises consists of the market radiating and integrating, micro-cooperation, organizational restructuring and cross-regional integration, and so on.
查看全文   查看/发表评论  下载PDF阅读器
关闭